Table 1.

Treatment schedule in the included paliperidone-LAI studies

Study	Patients randomized (N)	Randomization schedulea	Injection site	Initiation doses (mg eq.)		Maintenance doses (mg eq.)
				Day 1	Day 8
Pandina et al20	652	1:1:1:1	Deltoid	150	25, 50, or 100	25, 50, or 100
Kramer et al17	247	1:1:1	Gluteal	50 or 100	50 or 100	50 or 100
Gopal et al15	388	1:1:1:1	Gluteal	50, 100, or 150	50, 100, or 150	50, 100, or 150
Nasrallah et al19	518	1:1:1:1	Gluteal	25, 50, or 100	25, 50, or 100	25, 50, or 100

Notes:

^aAll studies had a placebo arm as one of the randomization arms; because doses of paliperidone LAI can be expressed either in mg eq. of the pharmacologically active fraction, paliperidone, or in mg of paliperidone LAI, the doses expressed as 25, 50, 100, and 150 mg eq. equate to 39, 78, 156, and 234 mg, respectively, of paliperidone LAI.

Abbreviations: mg eq., milligram equivalents; LAI, long-acting injectable.